Aardvark Therapeutics (AARD) Stock Price, News & Analysis

Company Overview

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders. Leveraging a proprietary screening platform, structural biology capabilities and medicinal chemistry expertise, Aardvark has advanced multiple preclinical candidates toward IND-enabling studies. These programs are supported by in vitro and in vivo pharmacology, biomarker development and toxicology assessments conducted at the company’s Cambridge research facilities.

Founded by a team of immunology and drug-development veterans, Aardvark Therapeutics is led by President and CEO Marshall Bolog, Ph.D. The leadership team combines translational pharmacology, clinical development and regulatory affairs expertise to guide the company’s pipeline through preclinical and early clinical stages. Aardvark pursues strategic collaborations with academic institutions and industry partners to enhance its RORγ portfolio and is positioned to advance its therapeutic candidates into human trials while exploring global licensing and development opportunities.

Key Stats

• Today's Range: $17.00 to $17.94
• 50-Day Range: $7.79 to $17.41
• 52-Week Range: $4.88 to $19.58
• Volume: 92,645 shs
• Average Volume: 235,102 shs
• Market Capitalization: $371.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.43
• Consensus Rating: Moderate Buy

Aardvark Therapeutics Stock Analysis - MarketRank™

Aardvark Therapeutics scored higher than 90% of companies evaluated by MarketBeat, and ranked 108th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Aardvark Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Aardvark Therapeutics has a consensus price target of $31.43, representing about 83.5% upside from its current price of $17.13.

Amount of Analyst Coverage

Aardvark Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.28% of the float of Aardvark Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aardvark Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aardvark Therapeutics has recently decreased by 39.26%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aardvark Therapeutics does not currently pay a dividend.

Dividend Growth

Aardvark Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.28% of the float of Aardvark Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aardvark Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aardvark Therapeutics has recently decreased by 39.26%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.51

News Sentiment

Aardvark Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Aardvark Therapeutics this week, compared to 3 articles on an average week.

Search Interest

10 people have searched for AARD on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.

MarketBeat Follows

9 people have added Aardvark Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Aardvark Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $305,630.00 in company stock and sold $0.00 in company stock.

AARD Stock Analysis - Frequently Asked Questions

How have AARD shares performed this year?

Aardvark Therapeutics' stock was trading at $13.30 at the start of the year. Since then, AARD stock has increased by 28.8% and is now trading at $17.13.

How were Aardvark Therapeutics' earnings last quarter?

Aardvark Therapeutics, Inc. (NASDAQ:AARD) released its quarterly earnings results on Wednesday, August, 13th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.52) by $0.14.

When did Aardvark Therapeutics IPO?

Aardvark Therapeutics (AARD) raised $100 million in an IPO on Friday, February 14th 2025. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets served as the underwriters for the IPO.

When did the company's lock-up period expire?

Aardvark Therapeutics's lock-up period expired on Tuesday, August 12th. Aardvark Therapeutics had issued 5,888,000 shares in its initial public offering on February 13th. The total size of the offering was $94,208,000 based on an initial share price of $16.00. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

How do I buy shares of Aardvark Therapeutics?

Shares of AARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/13/2025
• Today: 10/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AARD
• Previous Symbol: NASDAQ:AARD
• CIK: 1774857
• Web: N/A
• Phone: (858) 225-7696
• Fax: N/A
• Employees: 18
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Aardvark Therapeutics: $31.43
• High Price Target: $50.00
• Low Price Target: $19.00
• Potential Upside/Downside: +83.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.04
• Quick Ratio: 14.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 21,697,000
• Free Float: N/A
• Market Cap: $371.67 million
• Optionable: N/A
• Beta: N/A